Nanostructured lipid carriers: Versatile oral delivery vehicle

Future Science OA

Volumn 2, Issue 3, 2016, Pages

  Poonia, Neelam ^a   Kharb, Rajeev ^b   Lather, Viney ^a   Pandita, Deepti ^a  

^a JCDM College of Pharmacy   (India)

^b CT Group of Institutions   (India)

Author keywords

controlled drug release; gene drug delivery; nanoparticles

Indexed keywords

DRUG; EMULSIFYING AGENT; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; POLYMER; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ACTIVE TRANSPORT; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ENCAPSULATION; FIRST PASS EFFECT; HUMAN; MOUTH CAVITY; MUCOADHESION; PRIORITY JOURNAL; REVIEW; SURFACE PROPERTY; UNSPECIFIED SIDE EFFECT;

EID: 85026276848     PISSN: None     EISSN: 20565623     Source Type: Journal    
DOI: 10.4155/fsoa-2016-0030     Document Type: Review

References (106)

1. Pathak K, Raghuvanshi S. Oral bioavailability: issues and solutions via nanoformulations. Clin. Pharmacokinet. 54(4), 325-357 (2015).
2. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov. Today Technol. 9(2), 87-95 (2012).
3. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012, 1-10 (2012).
4. Silva AC, Santos D, Ferreira D, et al. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr. Med. Chem. 19(26), 4495-4510 (2012).
5. Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J. Pharm. Sci. 70(3), 269-277 (2008).
6. Peng SX, Ritchie DM, Cousineau M, et al. Altered oral bioavailability and pharmacokinetics of P-glycoprotein substrates by coadministration of biochanin A. J. Pharm. Sci. 95(9), 1984-1993 (2006).
7. Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7, 27-34 (2013).
8. Subramanian S, Singireddy A, Krishnamoorthy K, et al. Nanosponges: a novel class of drug delivery system-review. J. Pharm. Pharm. Sci. 15(1), 103-111 (2012).
9. Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat. Nanotechnol. 7(1), 41-55 (2013).
10. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in drug delivery system. Indian J. Pharm. Sci. 71(4), 349-358 (2009).
11. Iqbal MA, Md S, Sahni JK, et al. Nanostructured lipid carriers system: recent advances in drug delivery. J. Drug Target 20(10), 813-830 (2012).
12. Souto EB, Doktorovova S. Chapter 6-Solid lipid nanoparticle formulations pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol. 464, 105-129 (2009).
13. Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS Pharm. Sci. Tech. 12(1), 62-76 (2011).
14. Khan S, Baboota S, Ali J, et al. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int. J. Pharm. Investig. 5(4), 182-191 (2015).
15. Chaudhary S, Garg T, Murthy RS, et al. Development, optimization and evaluation of long chain nanolipid carrier for hepatic delivery of silymarin through lymphatic transport pathway. Int. J. Pharm. 485(1-2), 108-121 (2015).
16. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev. Ind. Pharm. 34(12), 1394-1405 (2008).
17. Tamjidi F, Shahedi M, Varshosaz J, et al. Nanostructured lipid carriers (NLC): a potential delivery system for bioactive food molecules. Innov. Food Sci. Emerg. Technol. 19, 29-43 (2013).
18. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int. J. Pharm. 415(1-2), 232-243 (2011).
19. Chen CC, Tsai TH, Huang ZR, et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 74(3), 474-482 (2010).
20. Yuan H, Wang LL, Du YZ, et al. Preparation and characteristics of nanostructured lipid carriers for controlreleasing progesterone by melt-emulsification. Colloids Surf. B Biointerfaces 60(2), 174-179 (2007).
21. Thatipamula R, Palem C, Gannu R, et al. Formulation and in vitro characterization of domperidone loaded solid lipid nanoparticles and nanostructured lipid carriers. Daru 19(1), 23-32 (2011).
22. Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis. 11, 159-179 (2012).
23. Luan J, Zheng F, Yang X, et al. Nanostructured lipid carriers for oral delivery of baicalin: in vitro and in vivo evaluation. Colloids Surf. A Physicochem. Eng. Asp. 466, 154-159 (2015).
24. Zhang X, Pan W, Gan L, et al. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull. 56(12), 1645-1650 (2008).
25. Wang Q, Cheng H, Zhou K, et al. Nanostructured lipid carriers as a delivery system of biochanin A. Drug Deliv. 20(8), 331-337 (2013).
26. Zhang T, Chen J, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci. 43(3), 174-179 (2011).
27. Kumbhar DD, Pokharkar VB. Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide: physicochemical investigations. Colloids Surf. A Physicochem. Eng. Asp. 416, 32-42 (2013).
28. Patil GB, Patil ND, Deshmukh PK, et al. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: application of factorial design approach. Artif. Cells Nanomed. Biotechnol. 44(1), 12-19 (2016).
29. Liu Y, Wang L, Zhao Y, et al. Nanostructured lipid carriers versus microemulsions for delivery of the poorly watersoluble drug luteolin. Int. J. Pharm. 476(1-2), 169-177 (2014).
30. Severino P, Souto EB, Pinho SC, et al. Hydrophilic coating of mitotane-loaded lipid nanoparticles: preliminary studies for mucosal adhesion. Pharm. Dev. Technol. 18(3), 577-581 (2013).
31. Zhou X, Zhang X, Ye Y, et al. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int. J. Pharm. 479(2), 391-398 (2015).
32. Aditya NP, Macedo AS, Doktorovova S, et al. Development and evaluation of lipid nanocarriers for quercetin delivery: a comparative study of solid lipid nanoparticles (SLN), nanostructured lipid carriers (NLC), and lipid nanoemulsions (LNE). LWT-Food Sci. Technol. 59(1), 115-121 (2014).
33. Beloqui A, Solinis MA, Delgado A, et al. Fate of nanostructured lipid carriers (NLCs) following the oral route: design, pharmacokinetics and biodistribution. J. Microencapsul. 31(1), 1-8 (2014).
34. Beloqui A, Solinis MA, Gascon AR, et al. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Rel. 166(2), 115-123 (2013).
35. Beloqui A, Solinis MA, Des Rieux A, et al. Dextranprotamine coated nanostructured lipid carriers as mucuspenetrating nanoparticles for lipophilic drugs. Int. J. Pharm. 468(1-2), 105-111 (2014).
36. Muchow M, Maincent P, Muller RH, et al. Production and characterization of testosterone undecanoate-loaded NLC for oral bioavailability enhancement. Drug Dev. Ind. Pharm. 37(1), 8-14 (2011).
37. Istrati D, Lacatusu I, Bordei N, et al. Phyto-mediated nanostructured carriers based on dual vegetable actives involved in the prevention of cellular damage. Mater. Sci. Eng. C Mater. Biol. Appl. 64, 249-259 (2016).
38. Abdelwahab SI, Sheikh BY, Taha MM, et al. Thymoquinone-loaded nanostructured lipid carriers: preparation, gastroprotection, in vitro toxicity, and pharmacokinetic properties after extravascular administration. Int. J. Nanomedicine 8, 2163-2172 (2013).
39. Zhuang CY, Li N, Wang M, et al. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int. J. Pharm. 394(1-2), 179-185 (2010).
40. Rahman HS, Rasedee A, Othman HH, et al. Acute toxicity study of zerumbone-loaded nanostructured lipid carrier on BALB/c mice model. Biomed. Res. Int. 1-15 (2014) (2014).
41. Hejri A, Khosravi A, Gharanjig K, et al. Optimisation of the formulation of beta-carotene loaded nanostructured lipid carriers prepared by solvent diffusion method. Food Chem. 141(1), 117-123 (2013).
42. Sun B, Luo C, Li L, et al. Core-matched encapsulation of an oleate prodrug into nanostructured lipid carriers with high drug loading capability to facilitate the oral delivery of docetaxel. Colloids Surf. B Biointerfaces 143, 47-55 (2016).
43. Zhang X, Qiao H, Zhang T, et al. Enhancement of gastrointestinal absorption of isoliquiritigenin by nanostructured lipid carrier. Adv. Powder Technol. 25(3), 1060-1068 (2014).
44. Shah NV, Seth AK, Balaraman R, et al. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: design and in vivo study. J. Adv. Res. 7(3), 423-434 (2016).
45. How CW, Rasedee A, Manickam S, et al. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf. B Biointerfaces 112, 393-399 (2013).
46. Shete H, Chatterjee S, De A, et al. Long chain lipid based tamoxifen NLC. Part II: pharmacokinetic, biodistribution and in vitro anticancer efficacy studies. Int. J. Pharm. 454(1), 584-592 (2013).
47. Tran TH, Ramasamy T, Truong DH, et al. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS Pharm. Sci. Tech. 15(6), 1509-1515 (2014).
48. Lacatusu I, Mitrea E, Badea N, et al. Lipid nanoparticles based on omega-3 fatty acids as effective carriers for lutein delivery. Preparation and in vitro characterization studies. J. Funct. Foods 5(3), 1260-1269 (2013).
49. Mendes AI, Silva AC, Catita JA, et al. Miconazole-loaded nanostructured lipid carriers (NLC) for local delivery to the oral mucosa: improving antifungal activity. Colloids Surf. B Biointerfaces 111, 755-763 (2013).
50. Lin C, Chen F, Ye T, et al. A novel oral delivery system consisting in 'drug-in cyclodextrin-in nanostructured lipid carriers' for poorly water-soluble drug: vinpocetine. Int. J. Pharm. 465(1-2), 90-96 (2014).
51. Tian Z, Yi Y, Yuan H, et al. Solidification of nanostructured lipid carriers (NLCs) onto pellets by fluid-bed coating: preparation, in vitro characterization and bioavailability in dogs. Powder Technol. 247, 120-127 (2013).
52. Mandpe L, Pokharkar V. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm. Dev. Technol. 20(3), 320-329 (2015).
53. Patil-Gadhe A, Pokharkar V. Montelukast-loaded nanostructured lipid carriers: part I oral bioavailability improvement. Eur. J. Pharm. Biopharm. 88(1), 160-168 (2014).
54. Date AA, Vador N, Jagtap A, et al. Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology 22(27), 102-110 (2011).
55. Ranpise NS, Korabu SS, Ghodake VN. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. Colloids Surf. B Biointerfaces 116, 81-87 (2014).
56. Tiwari R, Pathak K. Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int. J. Pharm. 415(1-2), 232-243 (2011).
57. Chen CC, Tsai TH, Huang ZR, et al. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur. J. Pharm. Biopharm. 74(3), 474-482 (2010).
58. Li W, Zhang T, Ye Y, et al. Enhanced bioavailability of tripterine through lipid nanoparticles using broccoli-derived lipids as a carrier material. Int. J. Pharm. 495(2), 948-955 (2015).
59. Averina ES, Muller RH, Popov DV, et al. Physical and chemical stability of nanostructured lipid drug carriers (NLC) based on natural lipids from Baikal region (Siberia, Russia). Pharmazie 66(5), 348-356 (2011).
60. Averina ES, Seewald G, Muller RH, et al. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil. Pharmazie 65(1), 25-31 (2010).
61. Manea A, Vasile BS, Meghea A. Antioxidant and antimicrobial activities of green tea extract loaded into nanostructured lipid carriers. Comptes Rendus Chimie 17(4), 331-341 (2014).
62. Velmurugan R, Selvamuthukumar S. Development and optimization of ifosfamide nanostructured lipid carriers for oral delivery using response surface methodology. Appl. Nanosci. 6(2), 159-173 (2015).
63. Helgason T, Awad TS, Kristbergsson K, et al. Impact of surfactant properties on oxidative stability of beta-carotene encapsulated within solid lipid nanoparticles. J. Agric. Food Chem. 57(17), 8033-8040 (2009).
64. Triplett MD, Rathman JF. Optimization of β-carotene loaded solid lipid nanoparticles preparation using a high shear homogenization technique. J. Nanopart. Res. 11(3), 601-614 (2008).
65. Tan SW, Billa N, Roberts CR, et al. Surfactant effects on the physical characteristics of amphotericin B-containing nanostructured lipid carriers. Colloids Surf. A Physicochem. Eng. Asp. 372(1-3), 73-79 (2010).
66. Wang L, Luo Q, Lin T, et al. PEGylated nanostructured lipid carriers (PEG-NLC) as a novel drug delivery system for biochanin A. Drug Dev. Ind. Pharm. 41(7), 1204-1212 (2015).
67. Zhang T, Chen J, Zhang Y, et al. Characterization and evaluation of nanostructured lipid carrier as a vehicle for oral delivery of etoposide. Eur. J. Pharm. Sci. 43(3), 174-179 (2011).
68. Liu CH, Wu CT. Optimization of nanostructured lipid carriers for lutein delivery. Colloids Surf. A Physicochem. Eng. Asp. 353(2-3), 149-156 (2010).
69. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 89(8), 967-978 (2000).
70. Porter CJ, Charman WN. Intestinal lymphatic drug transport: an update. Adv. Drug Deliv. Rev. 50(1-2), 61-80 (2001).
71. Yao M, McClements DJ, Xiao H. Improving oral bioavailability of nutraceuticals by engineered nanoparticle-based delivery systems. Curr. Opin. Food Sci. 2, 14-19 (2015).
72. Hu X, Fan W, Yu Z, et al. Evidence does not support absorption of intact solid lipid nanoparticles via oral delivery. Nanoscale 8(13), 7024-7035 (2016).
73. Chen Y, Yuan L, Zhou L, et al. Effect of cell-penetrating peptide-coated nanostructured lipid carriers on the oral absorption of tripterine. Int. J. Nanomedicine 7, 4581-4591 (2012).
74. Severino P, Andreani T, Macedo AS, et al. Current state-of-Art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J. Drug Deliv. 2012, 750891 (2012).
75. Suresh G, Manjunath K, Venkateswarlu V, et al. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm. Sci. Tech. 8(1), 1-24 (2007).
76. Fang G, Tang B, Chao Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol. Pharm. 12(7), 2384-2395 (2015).
77. Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J. Control. Rel. 127(2), 97-109 (2008).
78. Han HK, Lee BJ, Lee HK. Enhanced dissolution and bioavailability of biochanin A via the preparation of solid dispersion: in vitro and in vivo evaluation. Int. J. Pharm. 415(1-2), 89-94 (2011).
79. Fathi M, Mozafari MR, Mohebbi M. Nanoencapsulation of food ingredients using lipid based delivery systems. Trends Food Sci. Technol. 23(1), 13-27 (2012).
80. Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol. 18(3), 157-169 (2008).
81. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42(1), 59-98 (2003).
82. Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur. J. Clin. Invest. 33(Suppl. 2), 6-9 (2003).
83. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Deliv. Rev. 46(1-3), 89-102 (2001).
84. Zhou L, Chen Y, Zhang Z, et al. Preparation of tripterine nanostructured lipid carriers and their absorption in rat intestine. Pharmazie 67(4), 304-310 (2012).
85. Zhang C, Peng F, Liu W, et al. Nanostructured lipid carriers as a novel oral delivery system for triptolide: induced changes in pharmacokinetics profile associated with reduced toxicity in male rats. Int. J. Nanomedicine 9, 1049-1063 (2014).
86. Esposito E, Ravani L, Contado C, et al. Clotrimazole nanoparticle gel for mucosal administration. Mater. Sci. Eng. C Mater. Biol. Appl. 33(1), 411-418 (2013).
87. Gupta M, Vyas SP. Development, characterization and in vivo assessment of effective lipidic nanoparticles for dermal delivery of fluconazole against cutaneous candidiasis. Chem. Phys. Lipids 165(4), 454-461 (2012).
88. Albrecht K, Bernkop-Schnurch A. Thiomers: forms, functions and applications to nanomedicine. Nanomedicine 2(1), 41-50 (2007).
89. Zhang Q, Neoh KG, Xu L, et al. Functionalized mesoporous silica nanoparticles with mucoadhesive and sustained drug release properties for potential bladder cancer therapy. Langmuir 30(21), 6151-6161 (2014).
90. Gradauer K, Dunnhaupt S, Vonach C, et al. Thiomer-coated liposomes harbor permeation enhancing and efflux pump inhibitory properties. J. Control. Release 165(3), 207-215 (2013).
91. Muheem A, Shakeel F, Jahangir MA, et al. A review on the strategies for oral delivery of proteins and peptides and their clinical perspectives. Saudi Pharm. J. 24(4), 413-428 (2016).
92. Cone RA. Barrier properties of mucus. Adv. Drug Deliv. Rev. 61(2), 75-85 (2009).
93. Jokerst JV, Lobovkina T, Zare RN, et al. Nanoparticle PEGylation for imaging and therapy. Nanomedicine 6(4), 715-728 (2011).
94. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem. Int .Ed. Engl. 49(36), 6288-6308 (2010).
95. Sezgin Z, Yuksel N, Baykara T. Investigation of pluronic and PEG-PE micelles as carriers of meso-Tetraphenyl porphine for oral administration. Int. J. Pharm. 332(1-2), 161-167 (2007).
96. Nareoja T, Vehniainen M, Lamminmaki U, et al. Study on nonspecificity of an immuoassay using Eu-doped polystyrene nanoparticle labels. J. Immunol. Methods 345(1-2), 80-89 (2009).
97. Lundqvist M, Stigler J, Elia G, et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl Acad. Sci. USA 105(38), 14265-14270 (2008).
98. Panyam J, Sahoo SK, Prabha S, et al. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D, L-lactide-co-glycolide) nanoparticles. Int. J. Pharm. 262(1-2), 1-11 (2003).
99. Plapied L, Duhem N, Des Rieux A, et al. Fate of polymeric nanocarriers for oral drug delivery. Curr. Opin. Colloid Interface Sci. 16(3), 228-237 (2011).
100. Kuo YC, Wang CC. Cationic solid lipid nanoparticles with primary and quaternary amines for release of saquinavir and biocompatibility with endothelia. Colloids Surf. B. Biointerfaces 101, 101-105 (2013).
101. Liu L, Tang Y, Gao C, et al. Characterization and biodistribution in vivo of quercetin-loaded cationic nanostructured lipid carriers. Colloids Surf. B. Biointerfaces 115, 125-131 (2014).
102. Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption. Drug Disc. Today 19(7), 898-904 (2014).
103. Hashem FM, Nasr M, Khairy A. In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate. Pharm. Dev. Technol. 19(7), 824-832 (2014).
104. Mendes LP, Delgado JMF, Costa ADA, et al. Biodegradable nanoparticles designed for drug delivery: the number of nanoparticles impacts on cytotoxicity. Toxicol. In Vitro 29(6), 1268-1274 (2015).
105. Afshari M, Derakhshandeh K, Hosseinzadeh L. Characterisation, cytotoxicity and apoptosis studies of methotrexate-loaded PLGA and PLGA-PEG nanoparticles. J. Microencapsul. 31(3), 239-245 (2014).
106. How CW, Rasedee A, Abbasalipourkabir R. Characterization and cytotoxicity of nanostructured lipid carriers formulated with olive oil, hydrogenated palm oil, and polysorbate 80. IEEE Trans. Nanobioscience 12(2), 72-78 (2013).